Since periodontal ligament (PDL) cells exhibit several osteoblastic traits, we hypothesized that human PDL cells will respond to hormonal stimulation in an osteoblast-like manner. Confluent and pre-confluent PDL cells from six patients were challenged with PTH(1-34). Cell number, ALP, osteocalcin, osteoprotegerin, and RANKL expression were determined. Intermittent PTH(1-34) treatment of confluent PDL cells caused a significant increase in proliferation, whereas differentiation and osteoprotegerin production decreased significantly. In pre-confluent PDL cells, this treatment regimen induced a biphasic decrease in proliferation, but a biphasic increase in differentiation and osteoprotegerin production. Continuous PTH(1-34) exposure enhanced proliferation but inhibited osteocalcin production in confluent cells and stimulated osteoprotegerin production in pre-confluent PDL cells. RANKL was hardly detectable and unaffected by PTH(1-34) treatment. These results indicate that human PDL cells respond to PTH(1-34) in an osteoblast-like manner, and that the PTH(1-34) effect depends on the maturation state of the cells and on the mode of administration.
Get full access to this article
View all access options for this article.
References
1.
Barros SP, Silva MA, Somerman MJ, Nociti FH Jr -2003-. Parathyroid hormone protects against periodontitis-associated bone loss. J Dent Res82:791–795.
2.
Basdra EK, Komposch G -1997-. Osteoblast-like properties of human periodontal ligament cells: an in vitro analysis. Eur J Orthod19:615–621.
3.
Bos MP, van der Meer JM, Feyen JH, Herrmann-Erlee MP -1996-. Expression of the parathyroid hormone receptor and correlation with other osteoblastic parameters in fetal rat osteoblasts. Calcif Tissue Int58:95–100.
4.
Bretaudiere JP, Spillman T -1984-. Alkaline phosphatases. In: Methods of enzymatic analysis. Bergmeyer HU, editor. Weinheim: Chemica, pp. 75–92.
5.
Canalis E, Centrella M, Burch W, McCarthy TL -1989-. Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures. J Clin Invest83:60–65.
6.
Chen HL, Demiralp B, Schneider A, Koh AJ, Silve C, Wang C, et al. -2002-. Parathyroid hormone and parathyroid hormone-related protein exert both pro- and anti-apoptotic effects in mesenchymal cells. J Biol Chem277:19374–19381.
7.
Chou AM, Sae-Lim V, Lim T, Schantz J, Teoh S, Chew A, et al. -2002-. Culturing and characterization of human periodontal ligament fibroblasts—a preliminary study. Mater Sci Eng20:77–83.
8.
Gori F, Hofbauer LC, Dunstan CR, Spelsberg TC, Khosla S, Riggs BL -2000-. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology141:4768–4776.
9.
Halladay DL, Miles RR, Thirunavukkarasu K, Chandrasekhar S, Martin TJ, Onyia JE -2002-. Identification of signal transduction pathways and promoter sequences that mediate parathyroid hormone 1–38 inhibition of osteoprotegerin gene expression. J Cell Biochem84:1–11.
10.
Horwood NJ, Elliot J, Martin TJ, Gillespie MT -1998-. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology139:4743–4746.
11.
Huang JC, Sakata T, Pfleger LL, Bencsik M, Halloran BP, Bikle DD, et al. -2004-. PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res19:235–244.
12.
Iida-Klein A, Zhou H, Lu SS, Levine LR, Ducayen-Knowles M, Dempster DW, et al. -2002-. Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice. J Bone Miner Res17:808–816.
13.
Ishizuya T, Yokose S, Hori M, Noda T, Suda T, Yoshiki S, et al. -1997-. Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J Clin Invest99:2961–2970.
14.
Isogai Y, Akatsu T, Ishizuya T, Yamaguchi A, Hori M, Takahashi N, et al. -1996-. Parathyroid hormone regulates osteoblast differentiation positively or negatively depending on the differentiation stages. J Bone Miner Res11:1384–1393.
15.
Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC -1999-. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest104:439–446; comment 104:371–373.
16.
Kanzaki H, Chiba M, Shimizu Y, Mitani H -2001-. Dual regulation of osteoclast differentiation by periodontal ligament cells through RANKL stimulation and OPG inhibition. J Dent Res80:887–891.
17.
Kanzawa M, Sugimoto T, Kanatani M, Chihara K -2000-. Involvement of osteoprotegerin/osteoclastogenesis inhibitory factor in the stimulation of osteoclast formation by parathyroid hormone in mouse bone cells. Eur J Endocrinol142:661–664.
18.
Kondo H, Ohyama T, Ohya K, Kasugai S -1997-. Temporal changes of mRNA expression of matrix proteins and parathyroid hormone and parathyroid hormone-related protein -PTH/PTHrP- receptor in bone development. J Bone Miner Res12:2089–2097.
19.
Lee SK, Lorenzo JA -1999-. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology140:3552–3561.
20.
Ma YL, Cain R, Halladay D, Yang X, Zeng Q, Miles RR, et al. -2001-. Catabolic effects of continuous human PTH -1--38- in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology142:4047–4054.
21.
McCauley LK, Koh AJ, Beecher CA, Cui Y, Rosol TJ, Franceschi RT -1996-. PTH/PTHrP receptor is temporally regulated during osteoblast differentiation and is associated with collagen synthesis. J Cell Biochem61:638–647.
22.
Morley P, Whitfield JF, Willick GE -2001-. Parathyroid hormone: an anabolic treatment for osteoporosis. Curr Pharm Des7:671–687.
23.
Nakajima A, Shimoji N, Shiomi K, Shimizu S, Moriya H, Einhorn TA, et al. -2002-. Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone -1–34-. J Bone Miner Res17:2038–2047.
24.
Schiller PC, D’Ippolito G, Roos BA, Howard GA -1999-. Anabolic or catabolic responses of MC3T3-E1 osteoblastic cells to parathyroid hormone depend on time and duration of treatment. J Bone Miner Res14:1504–1512.
25.
Skripitz R, Aspenberg P -2001-. Early effect of parathyroid hormone -1–34- on implant fixation. Clin Orthop Relat Res392:427–432.
